Image 1
Trisenox Injection, Solution
Product Images NDC 63459-601
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Trisenox (NDC 63459-601). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cephalon, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image 2
The text is a chart showing survival rates for newly-diagnosed acute promyelocytic leukemia (APL) patients treated with ATRA-arsenic trioxide and ATRA-chemotherapy over a period of 6 months. The x-axis represents months since diagnosis, and the y-axis represents the percentage of patients who are event-free (i.e., have not experienced disease recurrence or death). The chart shows a higher event-free survival rate for those receiving ATRA-arsenic trioxide compared to those receiving ATRA-chemotherapy. The chart also includes a table showing the number of patients at risk for each treatment group at various time intervals.*
Image 3
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
